ATE532065T1 - Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl - Google Patents

Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl

Info

Publication number
ATE532065T1
ATE532065T1 AT03799763T AT03799763T ATE532065T1 AT E532065 T1 ATE532065 T1 AT E532065T1 AT 03799763 T AT03799763 T AT 03799763T AT 03799763 T AT03799763 T AT 03799763T AT E532065 T1 ATE532065 T1 AT E532065T1
Authority
AT
Austria
Prior art keywords
aisnhl
hearing loss
autoimmune
treatment
sensornetine
Prior art date
Application number
AT03799763T
Other languages
English (en)
Inventor
Thomas Carey
Thankam Nair
Jennifer Beckman
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE532065T1 publication Critical patent/ATE532065T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AT03799763T 2002-05-06 2003-05-06 Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl ATE532065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/139,496 US20030082646A1 (en) 1998-12-29 2002-05-06 Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
PCT/US2003/014248 WO2004041152A2 (en) 2002-05-06 2003-05-06 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl

Publications (1)

Publication Number Publication Date
ATE532065T1 true ATE532065T1 (de) 2011-11-15

Family

ID=32311697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799763T ATE532065T1 (de) 2002-05-06 2003-05-06 Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl

Country Status (6)

Country Link
US (2) US20030082646A1 (de)
EP (1) EP1508043B1 (de)
AT (1) ATE532065T1 (de)
AU (1) AU2003299473A1 (de)
CA (1) CA2489275C (de)
WO (1) WO2004041152A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082646A1 (en) * 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
US7829292B2 (en) * 2002-05-06 2010-11-09 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
EP1533319B1 (de) * 2002-06-27 2011-01-12 Nippon Medical School Foundation Verfahren zum nachweis von perilymphatischen fisteln
WO2006113723A2 (en) 2005-04-18 2006-10-26 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
WO2008070236A2 (en) * 2006-09-07 2008-06-12 The Cleveland Clinic Foundation Diagnostic assay for detecting and monitoring hearing loss
DE102008045696A1 (de) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
WO2020188573A1 (en) * 2019-03-21 2020-09-24 Gamida-Cell Ltd. Expanded nk cell fractions for transplantation in combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5422282A (en) * 1991-04-29 1995-06-06 The Regents Of The University Of California Methods for detecting autoimmune sensorineural hearing loss
US20010006788A1 (en) * 1998-12-29 2001-07-05 Thomas E. Carey Identifying the antigenic target of autoimmune sensorineural hearing loss (aisnhl) and developement of specific tests for diagnosis and management of aisnhl
US20030082646A1 (en) * 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
FR2800750B1 (fr) * 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
US20030022195A1 (en) * 2001-02-01 2003-01-30 Millennium Pharmaceuticals, Inc. 59914 and 59921, choline transporters and uses therefor

Also Published As

Publication number Publication date
EP1508043B1 (de) 2011-11-02
WO2004041152A2 (en) 2004-05-21
CA2489275A1 (en) 2004-05-21
WO2004041152A3 (en) 2004-10-14
EP1508043A2 (de) 2005-02-23
US20090075268A1 (en) 2009-03-19
CA2489275C (en) 2012-12-18
EP1508043A4 (de) 2006-09-06
US20030082646A1 (en) 2003-05-01
AU2003299473A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
Valdor et al. Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy
Arentz-Hansen et al. The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2006085984A3 (en) Immune cell biosensors and methods of using same
Lee et al. Examination of the anaerobic growth of Campylobacter concisus strains
TW200512298A (en) Method of diagnosing breast cancer
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE532065T1 (de) Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
IL151448A0 (en) Proteins
DE69935999D1 (de) Methoden zur introduktion heterologer zellen in fische
Simpson et al. Periodontal treatment causes a longitudinal increase in nitrite‐producing bacteria
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2020023789A3 (en) Small rna predictors for alzheimer's disease
SG163614A1 (en) Colon cancer related gene tom34
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
DE50208908D1 (de) Verfahren zur diagnose von chronisch entzündlichen darmerkrankungen
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
EP1815856A3 (de) Krebsimpfstoff
EP1332225A1 (de) Verfahren zur identifizierung abnormaler immunreaktionen
WO2006113723A3 (en) Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
Oikawa et al. Induction of potent antitumour natural‐killer cells from peripheral blood of patients with advanced prostate cancer
MX344494B (es) Inmunogeno y antiveneno contra el veneno de la araña violinista.